Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia

Ivetta Danylesko, Guy Chowers, Roni Shouval, Michal J. Besser, Elad Jacoby, Avichai Shimoni, Arnon Nagler, Abraham Avigdor

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose of the study: The prognosis of patients with relapsed/refractory precursor B-acute lymphoblastic leukemia (ALL) is dismal. Antibody-based therapies, such as blinatumomab or inotuzumab ozogamycin (IO) have led to improved outcomes. The impact of prior immunotherapy on chimeric antigen receptor (CAR) T-Cell therapeutic efficacy and toxicity is unknown. Methods: We describe a case series of ALL patients with prior exposure to blinatumomab or IO, who were treated with anti-CD19 CAR T cells with CD28 co-stimulatory domain (NCT02772198). We then review the literature on CAR-T post antibody-based therapy with either antibodies. Results: Five adult patients with B-ALL were included. Three had active disease, and two were in morphological complete remission (CR) with minimal residual disease (MRD+). Therapy before CAR-T included blinatumomab (3/5 [60 %]) and IO (3/5 [60 %]), with one patient receiving both. One patient experienced severe cytokine release syndrome and central nervous system toxicity and subsequently died. At 28 days following treatment, two patients achieved CR with MRD negativity, and two had an MRD + CR. Two patients received allogeneic hematopoietic stem cell transplantation. At a median of 10 months (range, 5–26, three out of the four patients are still in CR, and one relapsed. The literature review identified a deficiency on data on the influence of blinatumumab and IO on outcomes post CAR-T therapy. Conclusions: CD19 CAR T-cell therapy after treatment with blinatumomab and/or IO in patients with relapsed/refractory B-ALL is feasible and results in promising response rates in this case series. Future trails should specifically address outcomes in this population.

Original languageEnglish
Pages (from-to)17-22
Number of pages6
JournalCurrent Research in Translational Medicine
Volume68
Issue number1
DOIs
StatePublished - Jan 2020

Keywords

  • Acute lymphoblastic leukemia
  • Blinatumomab
  • Chimeric antigen receptor T cells
  • Inotuzumab ozogamycin

Fingerprint

Dive into the research topics of 'Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia'. Together they form a unique fingerprint.

Cite this